{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:43:29Z","timestamp":1782895409029,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":102,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K19607, 25K19589, 25HP8021"],"award-info":[{"award-number":["23K19607, 25K19589, 25HP8021"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"TOKIWA Pharmaceuticals Co., Ltd.","award":["Joint research funding"],"award-info":[{"award-number":["Joint research funding"]}]},{"name":"TOKIWA Pharmaceuticals Co., Ltd.","award":["Joint research funding"],"award-info":[{"award-number":["Joint research funding"]}]},{"name":"TOKIWA Pharmaceuticals Co., Ltd.","award":["Joint research funding"],"award-info":[{"award-number":["Joint research funding"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-026-00826-8","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:51:53Z","timestamp":1774101113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proteome-wide autoantibody screening and holistic autoantigenomic analysis unveil COVID-19 signature of autoantibody landscape"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9140","authenticated-orcid":false,"given":"Kazuki M.","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Iwadoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kurano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruyoshi","family":"Hisamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kuzumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takemichi","family":"Fukasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoshizaki-Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Miya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikako","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsunaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"826_CR1","first-page":"5346","volume":"5","author":"CS Grp","year":"2020","unstructured":"Grp CS, Version P. The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:5346\u2013544.","journal-title":"Nat Microbiol"},{"key":"826_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141\u201354.","journal-title":"Nat Rev Microbiol"},{"key":"826_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"295","author":"P Mehta","year":"2020","unstructured":"Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;295:1033\u20134.","journal-title":"Lancet"},{"key":"826_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"826_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12879-021-06536-3","volume":"21","author":"ZG Dessie","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality\u2013related risk factors of COVID\u201319: a systematic review and meta\u2013analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021;21:855.","journal-title":"BMC Infect Dis"},{"key":"826_CR6","unstructured":"Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Sci. 2020;370(80-)."},{"key":"826_CR7","unstructured":"Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~\u20094% of uninfected individuals over 70 years old and account for ~\u200920% of COVID-19 deaths. Sci Immunol. 2021;6."},{"key":"826_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s10875-022-01308-3","volume":"42","author":"S Eto","year":"2022","unstructured":"Eto S, et al. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19. J Clin Immunol. 2022;42:1360\u201370.","journal-title":"J Clin Immunol"},{"key":"826_CR9","doi-asserted-by":"publisher","first-page":"e78550","DOI":"10.7554\/eLife.78550","volume":"11","author":"SE Vazquez","year":"2022","unstructured":"Vazquez SE, et al. Autoantibody discovery across monogenic, acquired, and COVID-19-associated autoimmunity with scalable PhIP-seq. Elife. 2022;11:e78550.","journal-title":"Elife"},{"key":"826_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/s41551-022-00925-y","volume":"6","author":"JJ Credle","year":"2022","unstructured":"Credle JJ, et al. Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat Biomed Eng. 2022;6:992\u20131003.","journal-title":"Nat Biomed Eng"},{"key":"826_CR11","doi-asserted-by":"publisher","first-page":"e20211387","DOI":"10.1084\/jem.20211387","volume":"219","author":"A Puel","year":"2022","unstructured":"Puel A, Bastard P, Bustamante J, Casanova J-L. Human autoantibodies underlying infectious diseases. J Exp Med. 2022;219:e20211387.","journal-title":"J Exp Med"},{"key":"826_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00933-2","author":"A Cheng","year":"2023","unstructured":"Cheng A, Holland SM. Anti-cytokine autoantibodies: mechanistic insights and disease associations. Nat Rev Immunol. 2023. https:\/\/doi.org\/10.1038\/s41577-023-00933-2.","journal-title":"Nat Rev Immunol"},{"key":"826_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41590-023-01445-w","volume":"24","author":"J Muri","year":"2023","unstructured":"Muri J, et al. Autoantibodies against chemokines post-SARS-CoV-2 infection correlate with disease course. Nat Immunol. 2023;24:604\u201311.","journal-title":"Nat Immunol"},{"key":"826_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283\u20138.","journal-title":"Nature"},{"key":"826_CR15","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","volume":"12","author":"SE Chang","year":"2021","unstructured":"Chang SE, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417.","journal-title":"Nat Commun"},{"key":"826_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1038\/s41467-022-28905-5","volume":"13","author":"O Cabral-marques","year":"2022","unstructured":"Cabral-marques O, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun. 2022;13:1220.","journal-title":"Nat Commun"},{"key":"826_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.893086","volume":"13","author":"KM Matsuda","year":"2022","unstructured":"Matsuda KM, et al. Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Re fl ects Disease Status. Front Immunol. 2022;13:1\u201314.","journal-title":"Front Immunol"},{"key":"826_CR18","doi-asserted-by":"publisher","first-page":"102995","DOI":"10.1016\/j.jaut.2023.102995","volume":"135","author":"KM Matsuda","year":"2023","unstructured":"Matsuda KM, Kotani H, Yamaguchi K, Okumura T, Fukuda E. Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening. J Autoimmun. 2023;135:102995.","journal-title":"J Autoimmun"},{"key":"826_CR19","doi-asserted-by":"crossref","unstructured":"Kuzumi A, et al. Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1255540"},{"key":"826_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nmeth.1273","volume":"5","author":"N Goshima","year":"2008","unstructured":"Goshima N, et al. Human protein factory for converting the transcriptome into an in vitro-expressed proteome. Nat Methods. 2008;5:1011\u20137.","journal-title":"Nat Methods"},{"key":"826_CR21","doi-asserted-by":"publisher","first-page":"14652","DOI":"10.1073\/pnas.232580399","volume":"99","author":"T Sawasaki","year":"2002","unstructured":"Sawasaki T, Ogasawara T, Morishita R, Endo Y. A cell-free protein synthesis system for high-throughput proteomics. Proc Natl Acad Sci U S A. 2002;99:14652\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"826_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0014-5793(02)02329-3","volume":"514","author":"T Sawasaki","year":"2002","unstructured":"Sawasaki T, et al. A bilayer cell-free protein synthesis system for high-throughput screening of gene products. FEBS Lett. 2002;514:102\u20135.","journal-title":"FEBS Lett"},{"key":"826_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.copbio.2006.06.009","volume":"17","author":"Y Endo","year":"2006","unstructured":"Endo Y, Sawasaki T. Cell-free expression systems for eukaryotic protein production. Curr Opin Biotechnol. 2006;17:373\u201380.","journal-title":"Curr Opin Biotechnol"},{"key":"826_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/gtc.12832","volume":"26","author":"E Fukuda","year":"2021","unstructured":"Fukuda E, et al. Identification and characterization of the antigen recognized by the germ cell mAb TRA98 using a human comprehensive wet protein array. Genes Cells. 2021;26:180\u20139.","journal-title":"Genes Cells"},{"key":"826_CR25","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.1038\/s41467-025-66974-4","volume":"16","author":"KM Matsuda","year":"2025","unstructured":"Matsuda KM, et al. Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial. Nat Commun. 2025;16:10872.","journal-title":"Nat Commun"},{"key":"826_CR26","doi-asserted-by":"publisher","first-page":"102450","DOI":"10.1016\/j.autrev.2019.102450","volume":"19","author":"CP Moritz","year":"2020","unstructured":"Moritz CP, et al. Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19:102450. Autoantigenomics.","journal-title":"Autoimmun Rev"},{"key":"826_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ams2.789","volume":"9","author":"K Yamakawa","year":"2022","unstructured":"Yamakawa K, et al. Japanese rapid\/living recommendations on drug management for COVID -19: updated guidelines (July 2022). Acute Med Surg. 2022;9:1\u201321.","journal-title":"Acute Med Surg"},{"key":"826_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","volume":"131","author":"HC WILLIAMS","year":"1994","unstructured":"WILLIAMS HC, et al. The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis.: I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383\u201396.","journal-title":"Br J Dermatol"},{"key":"826_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts R, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222\u20137.","journal-title":"Ann Rheum Dis"},{"key":"826_CR30","doi-asserted-by":"crossref","unstructured":"Aringer M, et al. 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71:1400\u201312.","DOI":"10.1002\/art.40930"},{"key":"826_CR31","first-page":"1747","volume":"72","author":"F Van Den Hoogen","year":"2013","unstructured":"Van Den Hoogen F, et al. 2013 classification criteria for systemic sclerosis: An american college of rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 2013;72:1747\u201355.","journal-title":"Arthritis Rheum"},{"key":"826_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82428-5","volume":"11","author":"Y Nakano","year":"2021","unstructured":"Nakano Y, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021;11:1\u201310.","journal-title":"Sci Rep"},{"key":"826_CR33","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1515\/cclm-2020-0548","volume":"58","author":"C Qian","year":"2020","unstructured":"Qian C, et al. Development and multicenter performance evaluation of fully automated SARS-CoV-2 IgM and IgG immunoassays. Clin Chem Lab Med. 2020;58:1601\u20137.","journal-title":"Clin Chem Lab Med"},{"key":"826_CR34","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.molimm.2006.10.013","volume":"44","author":"DA Rhodes","year":"2007","unstructured":"Rhodes DA, Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol. 2007;44:2406\u201314.","journal-title":"Mol Immunol"},{"key":"826_CR35","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1002\/art.10521","volume":"46","author":"M Kuwana","year":"2002","unstructured":"Kuwana M, Kimura K, Kawakami Y. Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay. Arthritis Rheum. 2002;46:2742\u20137.","journal-title":"Arthritis Rheum"},{"key":"826_CR36","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1002\/art.21232","volume":"52","author":"M Kuwana","year":"2005","unstructured":"Kuwana M, et al. Enzyme-linked immunosorbent assay for detection of Anti\u2013RNA polymerase III antibody: Analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005;52:2425\u201332.","journal-title":"Arthritis Rheum"},{"key":"826_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"},{"key":"826_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tig.2013.05.010","volume":"29","author":"E Eisenberg","year":"2013","unstructured":"Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet. 2013;29:569\u201374.","journal-title":"Trends Genet"},{"key":"826_CR39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"The GTEx Consortium","year":"2020","unstructured":"The GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human. Sci (80-). 2020;369:1318\u201330.","journal-title":"Sci (80-)"},{"key":"826_CR40","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1002\/art.30399","volume":"63","author":"AM Morimoto","year":"2011","unstructured":"Morimoto AM, et al. Association of endogenous anti-interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:2407\u201315.","journal-title":"Arthritis Rheum"},{"key":"826_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-53356-5","volume":"15","author":"AF Jernbom","year":"2024","unstructured":"Jernbom AF, et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat Commun. 2024;15:1\u201314.","journal-title":"Nat Commun"},{"key":"826_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","volume":"13","author":"L Fagerberg","year":"2014","unstructured":"Fagerberg L, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom. 2014;13:397\u2013406.","journal-title":"Mol Cell Proteom"},{"key":"826_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/23808993.2020.1785286","volume":"5","author":"MC Deng","year":"2020","unstructured":"Deng MC. Multi-dimensional COVID-19 short- and long-term outcome prediction algorithm. Expert Rev Precis Med drug Dev. 2020;5:239\u201342.","journal-title":"Expert Rev Precis Med drug Dev"},{"key":"826_CR44","doi-asserted-by":"crossref","unstructured":"Huang Q, Szklarczyk D, Wang M, Simonovic M, von Mering C. PaxDb 5.0: Curated Protein Quantification Data Suggests Adaptive Proteome Changes in Yeasts. Mol Cell Proteom. 2023;22.","DOI":"10.1101\/2023.04.16.536357"},{"key":"826_CR45","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, et al. STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607\u201313.","journal-title":"Nucleic Acids Res"},{"key":"826_CR46","first-page":"79","volume":"12","author":"B Hooper","year":"1972","unstructured":"Hooper B, Whittingham S, Mathews JD, Mackay IR, Curnow DH. Autoimmunity in a rural community. Clin Exp Immunol. 1972;12:79\u201387.","journal-title":"Clin Exp Immunol"},{"key":"826_CR47","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/rheumatology\/keg096","volume":"42","author":"JPA Ioannidis","year":"2003","unstructured":"Ioannidis JPA, Katsifis GE, Stavropoulos ED, Manoussakis MN, Moutsopoulos HM. Evaluation of the association of autoantibodies with mortality in the very elderly: a cohort study. Rheumatology. 2003;42:357\u201361.","journal-title":"Rheumatology"},{"key":"826_CR48","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1111\/jgs.12533","volume":"61","author":"R Nisihara","year":"2013","unstructured":"Nisihara R, et al. Antinuclear Antibodies and Rheumatoid Factor Positivity in Healthy Elderly Adults: A Cross-Sectional Study in 336 Individuals. J Am Geriatr Soc. 2013;61:2044\u20136.","journal-title":"J Am Geriatr Soc"},{"key":"826_CR49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00134-021-06408-z","volume":"47","author":"U Trahtemberg","year":"2021","unstructured":"Trahtemberg U, et al. COVID-19-associated autoimmunity as a feature of acute respiratory failure. Intensive Care Med. 2021;47:801\u20134.","journal-title":"Intensive Care Med"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00826-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00826-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:44:28Z","timestamp":1782891868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12865-026-00826-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1186\/s12865-026-00826-8","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by The University of Tokyo Ethical Committee (Approval number 0695 and 2023051G). Written informed consent has been obtained from all the participants. All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was conducted under joint research contracts between The University of Tokyo and, respectively, ProteoBridge Corporation and TOKIWA Pharmaceutical Co., Ltd. A Yoshizaki and S Sato have received consultation fee from ProteoBridge Corporation. T Okamura belongs to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, supported by Chugai Pharmaceutical Corporation. K Yamaguchi, T Okumura, C Ono, Y Kobayashi, A Miya, A Sato, and N Goshima were employed by ProteoBridge Corporation. R Uchino, Y Murakami, and H Matsunaka were employed by TOKIWA Pharmaceutical Co., Ltd. K Fujio has additional collaborative research agreements with ProteoBridge Corporation outside the scope of this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}